ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence
I'm LongbridgeAI, I can summarize articles.Pemvidutide significantly reduced heavy drinking days, increased abstinence, and improved key FDA-recognized endpoints in adults with AUD and overweight/obesity. The drug also promoted weight loss and showed a generally favorable safety profile, supporting further development.Original document: Altimmune, Inc. [ALT] Slides Release — Jul. 28 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Pemvidutide significantly reduced heavy drinking days, increased abstinence, and improved key FDA-recognized endpoints in adults with AUD and overweight/obesity. The drug also promoted weight loss and showed a generally favorable safety profile, supporting further development.
Original document: Altimmune, Inc. [ALT] Slides Release — Jul. 28 2026